maybe SRX's new CEO will invigorate the R&D program

Sirtex  has $100 m cash in bank, but they only spent 4.7% of their FY16 sales on R&D. Apparently it's good practice for decent-sized pharmas to spend at least 10% of revenue on R&D to stay ahead.

SRX don't seem to have many advanced products in their pipeline. The SIR spheres have been very successful. But now  that story has hit a speed hump, SRX has been exposed as being a bit of a one-hit wonder.

They are exploring  SIR spheres for kidney cancer, but so far the results aren't that inspiring, with just one out of 19 patients showing a partial response.

They have talked about all sorts of research ideas, but nothing sounds very advanced beyond the SIR spheres.

If they can't come up with new radiotherapeutic products themselves, perhaps they could acquire a company that has advanced products

One such company is Telix.

It's a new, public but unlisted Australian company which has acquired an an impressive collection of  radiopharmaceuticals. and it has

a phase 3 product for treating kidney cancer,
a phase 2 product  for treating mestastised prostate cancer,
and a phase 1 product for treating brain cancer.

Pretty impressive, and a beautiful fit for Sirtex, maybe.

And people may be surprised by who the CEO is!
https://telixpharma.com/news/

Telix has done what Sirtex could do too - acquire  the modern variety of clinically advanced radiotherapeutics.

Maybe the new CEO, whoever it will be, will bring  fresh ideas and a bigger commitment to the R & D spend, and might even copy Telix's example and acquire some promising good-fit products.